Welcome to our dedicated page for Avidity Biosciences SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avidity Biosciences, Inc. (Nasdaq: RNA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into how Avidity describes its Antibody Oligonucleotide Conjugates (AOCs™) platform, its late-stage neuromuscular programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), and its broader pipeline in precision cardiology and immunology.
Current reports on Form 8-K are especially important for tracking material events at Avidity. Recent 8-K filings have covered topics such as the definitive merger agreement with Novartis AG, the related Separation and Distribution Agreement for the spin-off or sale of early-stage precision cardiology programs into SpinCo, positive clinical data from the EXPLORE44® and EXPLORE44-OLE™ trials of delpacibart zotadirsen (del-zota) in DMD44, and regulatory milestones including Breakthrough Therapy designation and updated BLA submission timing for del-zota. Other 8-Ks detail public equity offerings, amendments to equity incentive plans, and executive compensation arrangements in connection with the proposed merger.
Investors and analysts can also use Avidity’s SEC filings to confirm listing information for its common stock (trading under the symbol RNA on The Nasdaq Global Market), review descriptions of SpinCo and the planned spin-off structure, and understand the conditions, termination provisions and timing expectations associated with the Novartis transaction. These filings often reference additional documents such as proxy statements, registration statements for SpinCo and financial reports that further explain Avidity’s operations, risk factors and capital structure.
On Stock Titan, Avidity’s filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as clinical program updates, collaboration milestones, merger terms and changes in executive compensation. Real-time updates from EDGAR, combined with structured access to Forms 8-K and other filings, make this page a practical starting point for reviewing Avidity’s regulatory history, including material events related to its AOC platform, neuromuscular pipeline and the proposed acquisition by Novartis.
Michael F. MacLean, Chief Financial Officer of Avidity Biosciences, Inc. (RNA), reported insider stock sales on a Form 4. On 08/06/2025 he disposed of 30,914 shares of Avidity common stock under a Rule 10b5-1 trading plan adopted 07/08/2024 at a weighted-average price of $42.7264 per share (individual sale prices ranged from $40.15 to $43.92). After the reported transactions he beneficially owned 65,806 shares. The Form 4 was signed by an attorney-in-fact on 08/15/2025. The filing states the reporting person will provide details on the number of shares sold at each price upon request.
Avidity Biosciences insider Steven George executed transactions under a previously adopted Rule 10b5-1 plan, reducing his direct common stock holdings. On 08/13/2025 he acquired 1,542 shares via option exercise at a $6.57 exercise price and simultaneously sold 1,542 shares at $46.66 per share. After the transactions his direct beneficial ownership declined from 40,409 to 38,867 shares. The option that was exercised was granted on 09/11/2023 and vests monthly in equal installments, becoming fully exercisable on 09/11/2027. The 10b5-1 plan was adopted on 06/12/2024.
Avidity Biosciences (RNA) Form 144 notice: The filing reports a proposed sale of 9,709 common shares on 08/13/2025 through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $448,847.07. The securities were recorded as acquired on 08/13/2025 by exercise of stock options and paid in cash. The filing also discloses prior 10b5-1 sales by the same person on 08/06/2025 of 81,434 shares for $3,480,272.61. The filer represents they do not know any material nonpublic information.
Eric Mosbrooker, Chief Commercial Officer of Avidity Biosciences (RNA), reported option exercise and share sales on 08/06/2025. He exercised 124,687 stock options at an exercise price of $9.05, generating 124,687 common shares. Those shares and additional holdings were sold in multiple transactions under a Rule 10b5-1 trading plan adopted on September 11, 2024 at a weighted-average sale price of $44.0626 (range $40.54–$45.44).
The Form 4 shows total reported sales of 130,807 shares (124,687 + 6,120) and a reported direct beneficial ownership in common stock of 55,000 shares following the transactions. The filing also reports 190,313 derivative securities beneficially owned following the transactions and discloses an option vesting schedule of 1/48th monthly beginning January 1, 2024.
Troy Edward Wilson, a director of Avidity Biosciences, Inc. (RNA), executed option exercises and share sales on 08/06/2025 under a previously adopted Rule 10b5-1 trading plan. He exercised 22,000 options at an exercise price of $12.03 and 7,500 options at $12.48, and sold shares at $45.00 per share pursuant to the plan.
Following the reported transactions the filing shows 69,425 shares held directly by the reporting person. The Form 4 also lists indirect beneficial ownership via several irrevocable trusts and a family trust, shown as 285,000, 285,000, 17,776, 17,776, 11,851, 11,851, and 13,711 shares. The filing states the 10b5-1 plan was adopted on December 4, 2024 and that all option shares were fully vested and exercisable at the time of exercise.
Arthur A. Levin, a director of Avidity Biosciences (RNA), reported both the exercise of stock options and the sale of shares on 08/06/2025. He exercised options to acquire 107,500 shares at an exercise price of $22.34 per share; the option is noted as fully vested and exercisable. The same 107,500 shares were sold under a Rule 10b5-1 trading plan adopted on October 17, 2024 at a weighted-average price of $47.6175 per share, with trade prices reported in a range of $47.50–$48.02.
Following these transactions the reporting person directly beneficially owned 19,650 shares. The filing also discloses indirect holdings of 131,372 shares through a family trust and 22,500 shares through a charitable remainder trust. The related option shows an expiration date of 02/01/2031.
Steven George Hughes, Chief Medical Officer of Avidity Biosciences (RNA), reported multiple option exercises and subsequent sales on 08/06/2025. He exercised options with strike prices of $15.96, $6.57, $22.47, and $10.16, acquiring 11,283, 12,334, 6,167, and 17,667 shares respectively. Several of the acquired shares were sold the same day under a Rule 10b5-1 trading plan adopted June 12, 2024.
Sales were reported at a weighted-average price of $42.7373 with transaction prices ranging from $40.15 to $46.44. The filing shows the reporting person’s direct beneficial ownership of common stock following the transactions as 38,867 shares. The Form 4 also includes grant dates and monthly vesting schedules for each option grant.
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
What is the market cap of Avidity Biosciences (RNA)?
